$ cat ./records/gates-foundation-awards-second-5-million-menafrinet-grant-to-trac-2019.txt
Gates Foundation Awards Second $5 Million MenAfriNet Grant to Track Emerging Serogroup Shifts Across the Meningitis Belt
[RECORD.TXT] · cat --full
In 2019, the Gates Foundation awarded a second $5 million grant to the CDC Foundation for MenAfriNet, sustaining case-based surveillance and laboratory diagnostic capacity across Chad, Burkina Faso, Niger, Mali, and Togo. MenAfriNet's real-time data detected the rise of MenW and MenC serogroups following widespread MenAfriVac (serogroup A) deployment, directly informing next-generation meningococcal vaccine strategy — including the PATH/Biovac MenFive pentavalent ACWYX vaccine that received WHO prequalification in 2023.
Source: https://www.cdcfoundation.org/what/program/menafrinet-meningitis-surveillance-africa
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Breakthrough Energy Ventures Backs $90 Million Launch of Motif FoodWorks from Ginkgo Bioworks for Precision Fermentation Meat Proteins
Next →
Gates Foundation Funds Microneedle Patch for Needle-Free Measles-Rubella Vaccination Without Cold Chain
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.